Blue­Rock, Bay­er's stem cell group, de­tails glimpses of ef­fi­ca­cy in Parkin­son's dis­ease ther­a­py

A treat­ment that aims to re­store the dam­aged and dy­ing brain cells that cause un­con­trol­lable move­ments in Parkin­son’s dis­ease is show­ing promis­ing, al­beit ear­ly, signs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER